MAIA Biotechnology Email Formats
Biotechnology Research • 
Chicago, Illinois, United States • 21-50 Employees
MAIA Biotechnology Email Formats
MAIA Biotechnology uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@maiabiotech.com), used 62.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@maiabiotech.com | 62.5% |
{first name}{last name} | johndoe@maiabiotech.com | 18.8% |
{last name}{last name} | doedoe@maiabiotech.com | 18.8% |
Key Contacts at MAIA Biotechnology
Sean Stettnichs
Senior Director, Human Resources
Jean-Manassé Théagè
Member Board Of Directors
Vlad Vitoc
Founder And Ceo
Matthew Failor
Director, Head Of Clinical Operations
Stuart Byham
Sr. Director, Clinical Development And Operations
Stan V. Smith
Director
Ilgen Mender
Director, Biology Research
Marcel Mitsunaga
Director Business Analytics
Kenneth Hiser
Senior Director, Data Management
Company overview
| Headquarters | 444 West Lake Street, Suite 1700, Chicago, Illinois 60606, US |
| Phone number | +13124168592 |
| Website | |
| SIC | 873 |
| Keywords | Biotechnology, Research, Pharmaceutical, Oncology, Drug Development, Immunotherapy, Targeted Therapy, Small Molecule, Immmuno-Oncology, Telomere Targeting |
| Founded | 2018 |
| Employees | 21-50 |
| Socials |
About MAIA Biotechnology
MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
MAIA Biotechnology has 9 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore MAIA Biotechnology's funding history, including investment rounds, total capital raised, and key backers.
Funding Insights
$18,045,000
Total funding amount
$2,300,000
Most recent funding amount
9
Number of funding rounds
MAIA Biotechnology Tech Stack
Discover the technologies and tools that power MAIA Biotechnology's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
SEO
CDN
Tag managers
Reverse proxies
United Kingdom
South Africa
HaitiFrequently asked questions
4.8
40,000 users
